GLP1R and hepatocellular carcinoma: In contrast, in a large retrospective cohort study encompassing several types of cancer, Wang et al. found that compared with insulin, GLP-1R agonist use was associated with a significantly lower risk for gallbladder cancer, meningioma, pancreatic cancer, hepatocellular carcinoma, multiple myeloma, endometrial cancer, ovarian cancer, colorectal cancer, esophageal cancer, and kidney cancer (24).